Hooper A H, Tindall H, Barker M J, Spencer A A, Stainton C, Davies J A
Nucl Med Commun. 1986 May;7(5):349-54. doi: 10.1097/00006231-198605000-00004.
Nine patients with overt diabetic nephropathy underwent renal scintigraphy and measurement of platelet survival time using indium-111-labelled platelets after treatment for six weeks with aspirin-dipyridamole (990 mg/225 mg/day) or placebo in a double-blind cross-over study. External scanning of the renal areas at 16 and 40 h post-injection showed no excess activity of indium-111 relative to background. Mean platelet survival was within the published normal range at 9.1 +/- 0.6 days and 7.6 +/- 1.4 days using linear and gamma function analyses respectively. Treatment with aspirin-dipyridamole was without effect. The results suggest that significant platelet deposition in renal blood vessels is not an important factor in the pathogenesis of diabetic nephropathy.
在一项双盲交叉研究中,9名显性糖尿病肾病患者接受了肾脏闪烁扫描,并在使用阿司匹林 - 双嘧达莫(990毫克/225毫克/天)或安慰剂治疗六周后,使用铟 - 111标记的血小板测量血小板存活时间。注射后16小时和40小时对肾脏区域进行外部扫描显示,相对于背景,铟 - 111没有过量活性。使用线性和伽马函数分析,平均血小板存活时间分别在公布的正常范围内,即9.1±0.6天和7.6±1.4天。阿司匹林 - 双嘧达莫治疗无效。结果表明,肾血管中显著的血小板沉积不是糖尿病肾病发病机制中的重要因素。